Antibiotic-resistant infections are outpacing the drug pipeline, but a powerful, targeted solution has existed in nature all along.
Dev Mittar
Director, ASM Health Scientific Unit, American Society for Microbiology
Drug-resistant infections are no longer a distant threat. They are here, growing, and eroding a cornerstone of modern medicine: antibiotics. In the United States, according to the Centers for Disease Control and Prevention, 2.8 million antimicrobial-resistant infections occur each year. More patients will face bacterial infections that no antibiotic can treat, and the pipeline for new drugs cannot keep up. One of the most promising options for treating resistant infections already exists in nature: bacteriophages, the viruses that infect and kill bacteria. Yet despite their lifesaving potential, phage therapies remain underutilized in U.S. healthcare.
Phages offer a fundamentally different way to fight infections. They work by latching onto specific bacteria and hijacking them to make more phages, then releasing those new phages to repeat the cycle. They can target specific bacterial strains, avoiding collateral damage to good bacteria. In recent years, compassionate-use cases in the United States and abroad have shown phages rescuing patients from life-threatening, drug-resistant infections when nothing else worked. These successes are glimpses of what a more modern, tailored infectious-disease toolkit could look like.
The barriers to access
Phage therapy remains difficult to access. Clinicians who want to use phages face a maze of challenges, including limited manufacturing capacity, fragmented data on outcomes, and regulatory pathways that are not designed for personalized biological treatments. Hospitals often lack the infrastructure to identify which phages match which infections. Researchers struggle to coordinate clinical trials across institutions because cases are handled one by one, and the field lacks the robust, standardized evidence needed to move phage therapy into mainstream care. This fragmented system means that even when a desperately ill patient is identified as a candidate for phage therapy, securing treatment can take more than 50 days, a delay that can prove fatal for those battling life-threatening antibiotic-resistant infections.
A path forward
This is where international coordination becomes essential. Efforts like the ASM Health Phage Therapy Coordination Network illustrate what’s possible when scientists, clinicians, and regulators work together. The initiative focuses on improving data systems, supporting multicenter clinical trials, and helping hospitals navigate compassionate-use requests. This should be the start of a broader nationwide push.
If we are serious about confronting antimicrobial resistance, we need to treat phage therapy as a strategic priority. That means investing in manufacturing capacity, modernizing regulatory frameworks, leveraging modern tools, and building shared systems that allow clinicians to rapidly match patients with effective phages.
Phage therapy is not a silver bullet, but it is a powerful, targeted tool we have barely begun to use. With coordinated action, it can help slow the rise of drug-resistant infections and protect the future of medicine.
